← SynDRA
RO-4987655
SynDRA canonical compound SYN0025689 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MAP2K1 |
|---|
| Mechanism of action | MEK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MEK inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- NEK9
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- PHKG2
- PIM1
- PIM2
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2A
- PLK4
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NLK
- NEK7
- ABL1
- NEK3
- MAPKAPK3
Cross-references
Synonyms
- CH-4987655
- RO4987655
- RO-04927350
- MEK inhibitors (solid tumor), Roche
- CH 4987655
- I3733P75ML
- RefChem:930842
- MEK Inhibitor RO4987655
- CH4987655
- UNII-I3733P75ML
- C20H19F3IN3O5
- 3orn
- FIMYFEGKMOCQKT-UHFFFAOYSA-N
- MFCD19443685
- GTPL9910
- orb1301811
- SCHEMBL1562083
- SCHEMBL29358367
- SCHEMBL29363737
- GLXC-90458
- EX-A2312
- BDBM50338038
- NSC762521
- NSC800870
- AKOS005266648
- NSC-762521
- NSC-800870
- SB16732
- r-7167
- RO 4987655 [WHO-DD]
- compound 24 [PMID: 21316218]
- NCGC00378595-02
- NCGC00378595-03
- AC-36025
- AS-16322
- FD103047
- HY-14719
- DS-016573
Look up RO-4987655 in the interactive SynDRA portal →